Saturday 17 October 2026 Export PLX’s income statement to Excel — free account

Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024. In the quarter to June 2026, revenue grew 27.1%, EPS grew 2,281.0% and free cash flow fell 94.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.62 0.08 −2.96%

Follow PLX

Alert me

Market cap: $217.5M
P/E: 10.9×
Fwd P/E: 10.2×
Dividend yield: —
F-score: 3/9
Altman Z: −3.05
Beneish M: −0.15
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.17%

Capital & Financial Ratios $m

Market Cap 217.54

Revenue 80.62

Net Income 18.95

Free Cash Flow 7.67

Net Debt (41.38)

Current Ratio 2.94

Debt/Equity 0.00

P/E ratio 10.92

Fwd P/E 10.20

P/S ratio 2.60

P/B ratio 2.93

Past 5Y EPS Growth —

This Y EPS Growth 400.00%

Next Y EPS Growth (79.17%)

Next Y revenue growth (60.06%)

Next 5Y EPS Growth 110.55%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 48.43%

10-year low 10-year high

P/S against its own 10 years 62.81%

10-year low 10-year high

P/B against its own 10 years 36.51%

10-year low 10-year high

EV/Sales against its own 10 years 60.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	45	35	31	41
Receivables	5	3	9	17
Inventory	19	21	26	32
Other	1	1	1	2
	70	60	67	92

	2023	2024	2025	Q'26
Payables	24	24	25	30
ST’ Debt	—	—	—	—
Other	—	—	—	—
	46	26	27	31

Compound Annual Growth %

	10y	5y	3y
Sales	28.30%	(3.46%)	3.45%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	16.06%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	20	—	—	—
’25	10	16	18	9	53
’24	4	13	18	18	53
’23	10	35	10	10	65
’22	16	9	14	9	48
’21	11	6	12	9	38
’20	22	11	11	19	63

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	22	(10)	—	—	—
’25	(5)	(5)	(4)	2	(12)
’24	4	(4)	4	4	9
’23	(3)	5	(7)	4	(1)
’22	(6)	(7)	(9)	(3)	(25)
’21	(10)	7	(2)	(5)	(10)
’20	(7)	(8)	(4)	(8)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	21	(11)	—	—	—
’25	(5)	(6)	(4)	2	(14)
’24	4	(4)	4	4	7
’23	(3)	5	(7)	3	(2)
’22	(6)	(7)	(9)	(3)	(26)
’21	(10)	6	(2)	(6)	(12)
’20	(7)	(8)	(4)	(8)	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.22	0.05	—	—	—
’25	(0.05)	0.00	0.03	(0.07)	(0.08)
’24	(0.06)	(0.03)	0.03	0.09	0.04
’23	(0.05)	0.21	(0.02)	(0.07)	0.09
’22	(0.05)	(0.11)	(0.07)	(0.07)	(0.31)
’21	(0.14)	(0.25)	(0.09)	(0.14)	(0.62)
’20	0.10	(0.13)	(0.14)	0.03	(0.22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.60	3.80	2.70	1.70	2.04	0.79	0.70	1.21	0.82	1.32	Analyst estimates 2026–2028 Powerpack
	High	10.20	15.10	8.30	6.00	4.87	7.02	2.00	3.55	1.96	3.10
People
People	Employees	232	190	184	196	207	206	197	208	213	226
	Revenue/emp, $m	0.04	0.11	0.19	0.28	0.30	0.19	0.24	0.31	0.25	0.23
Income, $m
Income, $m	Revenue	9	21	34	55	63	38	48	65	53	53
	Gross margin, %	8.71	27.74	72.83	80.08	82.71	57.37	58.87	64.91	54.46	48.82
	EBT	(29)	(83)	(26)	(18)	(7)	(28)	(14)	9	4	(6)
	EBT margin, %	(317.16)	(395.86)	(77.27)	(33.42)	(10.37)	(71.92)	(30.22)	13.08	7.78	(10.63)
	Net income	(29)	(83)	(26)	(18)	(7)	(28)	(15)	8	3	(7)
	Depreciation	3	4	4	5	5	4	1	1	1	1
Per share, $
Per share, $	Revenue	0.91	1.61	2.33	3.69	2.16	0.87	0.98	0.97	0.74	0.67
	Earnings	(2.90)	(6.50)	(1.80)	(1.23)	(0.22)	(0.62)	(0.31)	0.12	0.04	(0.08)
	Cash flow	(3.17)	(0.76)	(0.53)	(1.30)	(0.90)	(0.23)	(0.52)	(0.02)	0.12	(0.15)
	Capex	(0.08)	(0.07)	(0.05)	(0.04)	(0.02)	(0.03)	(0.01)	(0.02)	(0.02)	(0.02)
	Free cash flow	(3.25)	(0.84)	(0.57)	(1.35)	(0.92)	(0.26)	(0.53)	(0.04)	0.10	(0.17)
	Book value	(0.98)	(2.25)	(3.59)	(4.74)	(0.93)	(0.14)	(0.22)	0.50	0.60	0.61
	Shares, m	10	13	15	15	29	44	48	68	73	79
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.00	47.00	0.00
	P/S	4.63	4.29	1.33	0.89	1.68	0.96	1.39	1.88	2.55	2.68
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.66	3.16	2.93
	EV/Sales	(0.15)	4.06	1.63	1.50	1.14	0.67	1.52	1.50	2.28	2.48
	EV/FCF	0.04	(7.80)	(6.62)	(4.09)	(2.68)	(2.18)	(2.83)	(39.90)	16.45	(9.58)
Cash, $m
Cash, $m	Operating cash flow	(32)	(10)	(8)	(19)	(26)	(10)	(25)	(1)	9	(12)
	Capex	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(2)
	Free cash flow	(33)	(11)	(8)	(20)	(27)	(12)	(26)	(2)	7	(14)
Balance, $m
Balance, $m	Working capital	6	40	28	(8)	(31)	28	12	24	34	40
	Total debt	19	46	48	51	4	28	28	—	—	—
	Net debt	(44)	(5)	10	33	(34)	(11)	6	(45)	(35)	(31)
	Shareholders’ equity	(10)	(29)	(53)	(70)	(27)	(6)	(11)	34	43	48
Returns, %
Returns, %	ROA	(32.72)	(108.04)	(39.68)	(34.31)	(11.51)	(38.96)	(23.06)	11.86	3.71	(8.48)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.21	(19.92)
	ROE	(6,411.57)	423.40	64.26	29.67	13.40	166.79	179.02	72.50	7.64	(14.44)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
PLX Protalix BioTherapeutics, Inc.	$217.5M	10.9×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
ALEC Alector, Inc.	$213.3M	— (loss-making)	— (loss-making)	−57.84% (below 0%: shrinking)	n/m	+30.19% (above 0%: growing)	100.00%	(734.73%)	Compare
IFRX InflaRx N.V.	$212.2M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+69.33% (above 0%: growing)	14,029.95%	0.00%	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$214.9M	—	—	−57.84%	—	+17.33%	100.00%	0.00%

All 614 Biotechnology stocks →

Protalix BioTherapeutics, Inc. (PLX) key facts

Concern: Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, PLX traded at $2.62, a market capitalization of $217.5 million.
Return on equity was −14.4% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.05 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.